SCHEMBL7987535

SCHEMBL7987535

CNC(=O)c1cc(Cl)ccc1Cl

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.67
TP53 P04637 1/20 0.59
SMN1; SMN2 Q16637 2/20 0.57
JAK2 O60674 1/20 0.56
JAK1 P23458 1/20 0.56
TYK2 P29597 1/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
HPGD P15428 1/20 0.56
CYP2C19 P33261 1/20 0.56
FLT1 P17948 1/20 0.56
FLT4 P35916 1/20 0.56
KDR P35968 1/20 0.56
TAS1R3 Q7RTX0 2/20 0.53
TAS1R1 Q7RTX1 2/20 0.53
TAS1R2 Q8TE23 1/20 0.53
ERCC5 P28715 1/20 0.51
FEN1 P39748 1/20 0.51
NPC1 O15118 1/20 0.51
SCN10A Q9Y5Y9 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3787454 0.86 ALDH1A1 (0.50) ALDH1A1TP53SMN1; SMN2SCN10APOLB
SCHEMBL4154496 0.84 KDM4E (0.67) ALDH1A1SMN1; SMN2JAK2JAK1TYK2
SCHEMBL29833777 0.84 KDM4E (0.67) ALDH1A1SMN1; SMN2JAK2JAK1TYK2
SCHEMBL12900908 0.82 SMN1; SMN2 (0.55) ALDH1A1SMN1; SMN2HPGDTAS1R3TAS1R1
SCHEMBL17481527 0.82 GAA (0.58) ALDH1A1TP53SMN1; SMN2TAS1R3TAS1R1
SCHEMBL824657 0.82 JAK2 (0.49) ALDH1A1SMN1; SMN2JAK2FLT1FLT4
SCHEMBL3871841 0.82 P2RX1 (0.64) KDRTAS1R3TAS1R1TAS1R2CA1
SCHEMBL3786490 0.82 SMN1; SMN2 (0.55) ALDH1A1SMN1; SMN2HPGDNPC1MEN1
Ammonia Solution, Strong SCHEMBL27375088 0.82 LMNA (0.65) ALDH1A1TP53SMN1; SMN2JAK2JAK1
SCHEMBL7985019 0.81 SMN1; SMN2 (0.54) ALDH1A1SMN1; SMN2HPGDLMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8377923-B2 Triazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2013-02-19 US disclosed
US-8377923-B2 Triazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2013-02-19 US disclosed
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-05-05 US disclosed
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-05-05 US disclosed
WO-2010001946-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF アステラス製薬株式会社 (JP) 2010-01-07 WO disclosed
EP-0636625-B1 Tricyclic diazepines vasopressin and oxytocin antagonists AMERICAN CYANAMID CO (US) 1999-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF HSD11B1, HSD11B2, HSD3B1 ALDH1A1 359/4885TP53 3435/4885SMN1; SMN2 3061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.